Humacyte (NASDAQ:HUMA) Announces Quarterly Earnings Results

Humacyte (NASDAQ:HUMA) announced its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07, Zacks reports.

Humacyte Price Performance

NASDAQ HUMA opened at $1.96 on Friday. The stock’s 50 day simple moving average is $3.61 and its 200 day simple moving average is $4.51. Humacyte has a one year low of $1.76 and a one year high of $9.97. The firm has a market cap of $246.68 million, a PE ratio of -1.46 and a beta of 1.36.

Wall Street Analyst Weigh In

Several research firms recently issued reports on HUMA. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. Benchmark reissued a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.